Using its proprietary PreEMT™ high pressure folding technology, BaroFold aims to discover, develop, and commercialize protein biologics that improve the tolerability, efficacy, and safety of a wide variety of protein therapeutics, with a pipeline focused on immunology indications such as Multiple Sclerosis, Rheumatoid Arthritis, and Asthma. Its technology enables the creation of novel protein therapeutics, accelerates therapeutic protein development, and enables life-cycle management of protein therapeutics for bio-pharmaceutical companies, research institutions, and government agencies.